In AML patients, the levels of DNMT3A mutations do not correlate with presenting clinical features or concurrent gene mutations and do not affect the OS; DNMT3A-mut expression persists in most AML patients achieving complete remission after induction chemotherapy, suggesting the persistence of clonal hematopoiesis in hematological remission [31]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.